Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK plus NSCLC

被引：0
|
作者：
Kumar, Pragya
Turati, Virginia
Marusyk, Andriy
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 10期
关键词：
D O I：
10.1158/1538-7445.EVODYN22-B032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B032
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now
    Passaro, Antonio
    Peters, Solange
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1325 - 1327
  • [22] Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment
    Hotta, Katsuyuki
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Murakami, Haruyasu
    Ohe, Yuichiro
    Takeda, Koji
    Yoshimoto, Takuya
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S648 - S648
  • [23] Alectinib shows CNS efficacy in ALK-positive NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E520 - E520
  • [24] Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2017, 18 (07): : E377 - E377
  • [25] Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK plus advanced NSCLC (aNSCLC).
    Kim, Dong-Wan
    Gadgeel, Shirish M.
    Gettinger, Scott N.
    Riely, Gregory J.
    Oxnard, Geoffrey R.
    Mekhail, Tarek
    Schmid, Peter
    Dowlati, Afshin
    Heist, Rebecca Suk
    Wozniak, Antoinette J.
    Hernandez, Genevive
    Sarkar, Indrani
    Mitry, Emmanuel
    Foster, Paul
    O'Hear, Carol
    Spahn, Jessica
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Adjuvant alectinib improves outcomes in ALK-mutant NSCLC
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (07) : 484 - 484
  • [27] Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
    Ji, Jingran
    Mitra, Anupam
    Camidge, D. Ross
    Riess, Jonathan W.
    CLINICAL LUNG CANCER, 2021, 22 (06) : E851 - E855
  • [28] Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
    Lopez Castro, R.
    Insa Molla, A.
    Esteban Gonzalez, E.
    Gomez Rueda, A.
    Isla Casado, D.
    Barneto Aranda, I.
    Bayona Anton, C.
    Majem Tarruella, M.
    Peralta Munoz, S.
    Garcia Campelo, R.
    Bosch Barrera, J.
    Juan Vidal, O. J.
    Bernabe Caro, R.
    Vicente Baz, D.
    Gordo Flores, R.
    Carrizo Mijarra, N.
    Ferrer Sanchez, I.
    Lopez Munoz, M. E.
    Ponce Aix, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E13 - E14
  • [29] Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK plus NSCLC): Second interim analysis of ALCURE
    Mouri, A.
    Tsuda, T.
    Oki, M.
    Ichihara, E.
    Tanaka, H.
    Azuma, K.
    Arai, R.
    Kuyama, S.
    Akamatsu, H.
    Otsubo, K.
    Ajimizu, H.
    Matsumoto, M.
    Seto, Y.
    Uchibori, K.
    Hayashi, H.
    Miyauchi, E.
    Ishizuka, N.
    Kajihara, Y.
    Nakagawa, Y.
    Katayama, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1644 - S1645
  • [30] Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK- Rearranged NSCLC
    Daniel, Catherine
    Callens, Celine
    Melaabi, Samia
    Bieche, Ivan
    Girard, Nicolas
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
12345